Arecor Limited. the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart, NovoRapid®, and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020. Abstract #55 is available online.
Cambridge, UK and San Diego, CA, 17th September 2020 – Abzena, a fully integrated global development and GMP manufacturing partner for the biopharmaceutical industry, has been announced as the winner of the Best Contract Research (CRO) category at the World ADC Awards 2020.
• Mogrify recognized for furthering life science discovery for the benefit of human healthcare through direct cellular conversion technology
• Co-founder and CSO receives award celebrating his achievements in establishing Mogrify
The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.